Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancer
(MedPage Today) -- A first-in-class bispecific antibody achieved durable responses in a fourth of patients with advanced small cell lung cancer (SCLC) and disease control in more than half, a preliminary clinical trial showed.
Tarlatamab, targeting...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Hematology | Lung Cancer | Small Cell Lung Cancer